Safety and Tolerability of MEDI0562, an OX40 Agonist mAb, in Combination with Durvalumab or Tremelimumab in Adult Patients with Advanced Solid Tumors

Autor: Jonathan W. Goldman, Sarina A. Piha-Paul, Brendan Curti, Katrina S. Pedersen, Todd M. Bauer, Stefanie L. Groenland, Richard D. Carvajal, Vaishali Chhaya, Gray Kirby, Kelly McGlinchey, Scott A. Hammond, Katie Streicher, Danielle M. Townsley, Young Kwang Chae, Jens Voortman, Aurelien Marabelle, John Powderly

Publikováno v: Clinical cancer research : an official journal of the American Association for Cancer Research, 28(17), 3709-3719. American Association for Cancer Research Inc.
Goldman, J W, Piha-Paul, S A, Curti, B, Pedersen, K S, Bauer, T M, Groenland, S L, Carvajal, R D, Chhaya, V, Kirby, G, McGlinchey, K, Hammond, S A, Streicher, K, Townsley, D M, Chae, Y K, Voortman, J, Marabelle, A & Powderly, J 2022, ' Safety and Tolerability of MEDI0562, an OX40 Agonist mAb, in Combination with Durvalumab or Tremelimumab in Adult Patients with Advanced Solid Tumors ', Clinical cancer research : an official journal of the American Association for Cancer Research, vol. 28, no. 17, pp. 3709-3719 . https://doi.org/10.1158/1078-0432.CCR-21-3016

Purpose: Combination therapies targeting immunologic checkpoints have shown promise in treating multiple tumor types. We report safety and tolerability of MEDI0562, a humanized IgG1K OX40 mAb, in combination with durvalumab (anti-PD-L1), or tremelimu

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dc2ae1dee17b1c4274c5fa067c0313f8
https://doi.org/10.1158/1078-0432.ccr-21-3016

Supplementary Figure from Safety and Tolerability of MEDI0562, an OX40 Agonist mAb, in Combination with Durvalumab or Tremelimumab in Adult Patients with Advanced Solid Tumors

Autor: John Powderly, Aurelien Marabelle, Jens Voortman, Young Kwang Chae, Danielle M. Townsley, Katie Streicher, Scott A. Hammond, Kelly McGlinchey, Gray Kirby, Vaishali Chhaya, Richard D. Carvajal, Stefanie L. Groenland, Todd M. Bauer, Katrina S. Pedersen, Brendan Curti, Sarina A. Piha-Paul, Jonathan W. Goldman

Supplementary Figure from Safety and Tolerability of MEDI0562, an OX40 Agonist mAb, in Combination with Durvalumab or Tremelimumab in Adult Patients with Advanced Solid Tumors

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4a03147e35ccf0f48c28148c327500f9
https://doi.org/10.1158/1078-0432.22487267.v1

Cortical Bone Thickness and Bone Mineral Density

Autor: Vaishali Chhaya, Souhail G. Shamiyeh, Eli Shamiyeh

Publikováno v: Journal of Clinical Densitometry. 16:127-128

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::81f00db5448b0d401f105bd5a49feeba
https://doi.org/10.1016/j.jocd.2012.07.007